Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05065866 · ClinicalTrials.gov registry record · Phase 1
Duvelisib in Combination With BMS-986345 in Lymphoid Malignancy
A Phase 1 study of Non-Hodgkin Lymphoma and Hodgkin Lymphoma, sponsored by H. Lee Moffitt Cancer Center and Research Institute.
- Completed
- Registry status
- Phase 1
- Development phase
- 14
- Enrollment target
- 1
- Study location
NCT05065866 is a Phase 1 study of Non-Hodgkin Lymphoma and Hodgkin Lymphoma that has completed, run by H. Lee Moffitt Cancer Center and Research Institute. The registered enrollment target is 14 participants, below the 152-participant average among 104 other Non-Hodgkin Lymphoma trials with a reported enrollment target (91% lower). The trial reports 1 study location across 1 state.
The verdict
NCT05065866, a Phase 1 study of Non-Hodgkin Lymphoma and Hodgkin Lymphoma, has completed, sponsored by H. Lee Moffitt Cancer Center and Research Institute.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 14 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of the study is to find a safe dose and to evaluate the safety and tolerability of the drug BMS-986345, in combination with duvelisib.
Conditions Studied
Interventions
- DRUG Duvelisib
- DRUG BMS-986345
Study Locations (1)
Florida
- Moffitt Cancer Center - Tampa
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2021-11-18 |
| Est. Completion | 2024-04-24 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05065866
The ClinicalTrials.gov registry entry for NCT05065866 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 14 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 152-participant average among 104 other Non-Hodgkin Lymphoma trials with a reported enrollment target (91% lower). The listed sponsor is H. Lee Moffitt Cancer Center and Research Institute, which has 502 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with Non-Hodgkin Lymphoma appearing as the primary indexed condition, and to 2 interventions - of which Duvelisib is the first listed.
NCT05065866 reports 1 study location spanning 1 distinct geographic area - top geographies include Florida.
Frequently Asked Questions
What is clinical trial NCT05065866 about?
NCT05065866 is a clinical study titled "Duvelisib in Combination With BMS-986345 in Lymphoid Malignancy". The purpose of the study is to find a safe dose and to evaluate the safety and tolerability of the drug BMS-986345, in combination with duvelisib.
What is the current status of trial NCT05065866?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 14 participants. The study started on 2021-11-18. Estimated completion is 2024-04-24.
What conditions does trial NCT05065866 study?
This clinical trial studies the following conditions: Non-Hodgkin Lymphoma, Hodgkin Lymphoma, Myeloma, Lymphocytic Leukemia.
What interventions are being tested in trial NCT05065866?
The interventions under investigation include: Duvelisib (DRUG), BMS-986345 (DRUG).
Who is sponsoring clinical trial NCT05065866?
This trial is sponsored by H. Lee Moffitt Cancer Center and Research Institute, which has 502 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05065866 being conducted?
This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Non-Hodgkin Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Safety and Efficacy Study Evaluating CTX112 in Subjects With Relapsed or Refractory B-Cell Malignancies
RECRUITING · Phase 1
-
Study of Cytokine Release Syndrome Prophylaxis and Treatment With Siltuximab Prior to Epcoritamab
RECRUITING · Phase 1
-
Dose-escalation and Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Participants With Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and r/r B-cell Acute Lymphoblastic Leukemia (B-ALL)
RECRUITING · Phase 1
-
Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid Tumors
RECRUITING · Phase 1
-
Preliminary Safety and Tolerability of CD19x22 CAR T Cells in Adolescent and Adult R/R B-NHL Patients
RECRUITING · Phase 1
-
Activated T-Cells Expressing 2nd or 3rd Generation CD19-Specific CAR, Advanced B-Cell NHL, ALL, and CLL (SAGAN)
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.